EORTC-2227-BTG - Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study

Studio Clinico

Patologia: Neoplasie cerebrali

Osservazionale-Sperimentale: Sperimentale

Monocentrico-Multicentrico: Multicentrico

Randomizzato: Sì

Fase di studio: III

Linee di trattamento: Seconda linea

Criteri di inclusione: 

- Before patient's enrolment, written informed consent must be given according to ICH/GCP, and national/local regulations.
- Patients with first progression or recurrent glioblastoma after standard chemoradiotherapy (any treatment other than use of nitroureas) having occurred at least 6 months after the end of prior radiotherapy
- Measurable disease according to RANO criteria with a maximum tumour diameter of 5 cm (local investigator assessment)
- In case of surgery for recurrence: fully recovered from surgery, confirmation of recurrence by histology, and patient fit for treatment as per local investigator assessment.
- Histologically proven diagnosis of glioblastoma, IDH wildtype per WHO 2021 classification and local assessment of tissue from diagnosis or recurrence
- Initial treatment of newly diagnosed glioblastoma by maximal safe resection and postsurgical concurrent conventionally fractionated or abbreviated (minimum 15 fractions) chemoradiotherapy with or without maintenance chemotherapy with temozolomide (patient must have received at least one dose)
- Stable or decreasing dose of steroids for 7 days prior to enrolment
- Age ≥ 18 years
- WHO Performance status of 0-2
- Women of childbearing potential (WOCBP) must have a negative serum pregnancy test within 7 days prior to the first dose of study treatment.
- Patients of childbearing / reproductive potential must agree to use adequate birth control measures during the study treatment period and for at least 6 months after the last dose of study treatment. A highly effective method of birth control is defined as a method which results in a low failure rate (i.e., less than 1% per year) when used consistently and correctly.
- Female subjects who are breast feeding should discontinue nursing prior to the first dose of study treatment and until 6 months after the last study treatment.
- Non-sterile males must use contraception during treatment and for 6 months after the last dose.
- Non-sterile males must avoid sperm donation for the duration of the study and for at least 6 months after the last dose of study treatment.

Criteri di esclusione: 

- Any prior anticancer treatment for recurrent glioblastoma (except surgery)
- Significant reduction in thrombocyte and/or leukocyte counts as well as severe renal impairment according to investigator's opinion
- History or present acute leukaemia or any myeloid disease
- Known hypersensitivity to the active components or excipients of lomustine
- Known coeliac disease or wheat allergy
- Live attenuated vaccine in the 3 months prior to lomustine initiation
- Any serious or uncontrolled medical condition (e.g., infections, chronic alcoholism, drug addiction) or abnormality, in the judgment of the investigator that prohibits obtaining informed consent, safe participation and study completion
- Known contraindication to imaging tracer or any product of contrast media and Magnetic Resonance Imaging (MRI) contraindications
- Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be assessed and discussed with the patient before the enrolment in the trial.

Trattamento sperimentale: 

Lomustine plus reirradiation

Trattamento di controllo: 

Lomustine alone

Centri partecipanti

Nord Italia

Centro Italia

Informazioni Generali

Protocollo

Numero di iscrizione a registro: 2023-505267-36-00

Data di inserimento: 04.12.2025

Promotore

EORTC - European Organisation for Research and Treatment of Cancer

Principal Investigator ITALIA

Riferimento: Dr. Info non applicabile

Telefono: 00000

Email: na@na.it

Localita: na